☆ 4.7 Article

Second messenger signalling bypasses CGRP receptor blockade to provoke migraine attacks in humans

BRAIN (2023)

Related references

Note: Only part of the references are listed.

Article Clinical Neurology

The PACAP pathway is independent of CGRP in mouse models of migraine: possible new drug target?

Charlotte Ernstsen et al.

Summary: Using in vivo and ex vivo models, the study shows that PACAP-38 can provoke migraine-like changes independently of CGRP and partially through K-ATP channels. The findings suggest that PACAP-38 antagonism could be a potential alternative therapeutic approach for patients non-responsive to CGRP-targeting therapies.

BRAIN (2022)

Add to Collection

Review Pharmacology & Pharmacy

Beyond CGRP: The calcitonin peptide family as targets for migraine and pain

Tayla A. Rees et al.

Summary: In addition to CGRP, calcitonin family peptides may be therapeutically useful in treating migraines and other pain disorders. Their localization in peripheral pain pathways could play a role in migraines and pain.

BRITISH JOURNAL OF PHARMACOLOGY (2022)

Add to Collection

Article Neurosciences

Human and mouse trigeminal ganglia cell atlas implicates multiple cell types in migraine

Lite Yang et al.

Summary: This study developed a cell atlas of trigeminal ganglion cells in humans and mice, providing insights into the gene expression patterns and gene regulatory elements of different cell types. The atlas identified cell types implicated in migraine and provides a valuable resource for understanding headache pathophysiology and developing more selective treatments.

NEURON (2022)

Add to Collection

Review Clinical Neurology

Nocebo response in human models of migraine: A systematic review and meta-analysis of randomized, double-blind, placebo-controlled, two-way crossover trials in migraine without aura and healthy volunteers

Hashmat Ghanizada et al.

Summary: Human models of migraine have been used for three decades to test trigger molecules, but the nocebo effects have not been systematically explored. A systematic review and meta-analysis showed a low nocebo response rate in randomised clinical trials using human models of migraine.

CEPHALALGIA (2021)

Add to Collection

Article Clinical Neurology

Amylin Analog Pramlintide Induces Migraine-like Attacks in Patients

Hashmat Ghanizada et al.

Summary: This study investigated the role of pramlintide in the pathogenesis of migraine, finding that it participates in migraine attacks through activation of the amylin receptor. Through experiments on patients and studies on animal models, it was discovered that pramlintide and CGRP have similar effects in inducing migraine-like symptoms.

ANNALS OF NEUROLOGY (2021)

Add to Collection

Review Medicine, General & Internal

Migraine: integrated approaches to clinical management and emerging treatments

Messoud Ashina et al.

Summary: Migraine is a highly disabling neurological disorder affecting over 1 billion people worldwide. Treatment options include pharmacological and non-pharmacological therapies. Building a personalized treatment plan and exploring emerging mechanism-based treatments are crucial for effective management.

LANCET (2021)

Add to Collection

Review Medicine, General & Internal

Migraine: disease characterisation, biomarkers, and precision medicine

Messoud Ashina et al.

Summary: The paper discusses the progress made in the search for biomarkers of migraine within genetics, provocation modeling, biochemistry, and neuroimaging research. Challenges and future directions for each biomarker modality are outlined, as well as advances in combining and integrating data from multiple biomarker modalities. These efforts contribute to developing precision medicine for future patients with migraine.

LANCET (2021)

Add to Collection

Review Medicine, General & Internal

Migraine: epidemiology and systems of care

Messoud Ashina et al.

Summary: Migraine is a global neurovascular disorder that has negative impacts on patients, families, and society. Integrated and coordinated care systems can help reduce this burden. Low and middle-income countries face challenges in migraine care due to inadequate public health education and access to medication.

LANCET (2021)

Add to Collection

Article Clinical Neurology

Effect of Adrenomedullin on Migraine-Like Attacks in Patients With Migraine A Randomized Crossover Study

Hashmat Ghanizada et al.

Summary: The study confirms that IV infusion of adrenomedullin may trigger migraine attacks, leading to increased headache intensity and changes in physiological indicators such as heart rate and flushing.

NEUROLOGY (2021)

Add to Collection

Article Anesthesiology

Opening of BKCa channels causes migraine attacks: a new downstream target for the treatment of migraine

Mohammad Al-Mahdi Al-Karagholi et al.

Summary: This study found that BKCa channel opening may trigger migraine attacks, and BKCa channel blockers could be potential candidates for novel antimigraine drugs.

PAIN (2021)

Add to Collection

Article Clinical Neurology

CGRP-dependent signalling pathways involved in mouse models of GTN- cilostazol- and levcromakalim-induced migraine

Sarah L. Christensen et al.

Summary: The study investigated the signalling pathways involved in three different mouse models of provoked migraines, finding that all three models involve calcitonin gene-related peptide signalling. The results suggest a complex interplay between different cell/tissue types in migraine pathophysiology.

CEPHALALGIA (2021)

Add to Collection

Article Clinical Neurology

Effect of Adrenomedullin on Migraine-Like Attacks in Patients With Migraine

Hashmat Ghanizada et al.

Summary: The IV infusion of adrenomedullin was found to increase the incidence and intensity of migraine attacks, as well as significant adverse effects on heart rate and flushing. The study suggests that adrenomedullin may be a potential therapeutic target for migraine treatment.

NEUROLOGY (2021)

Add to Collection

Review Medicine, General & Internal

Migraine

Messoud Ashina

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Clinical Neurology

Effect of the H1-antihistamine clemastine on PACAP38 induced migraine

Luise Haulund Vollesen et al.

CEPHALALGIA (2019)

Add to Collection

Article Clinical Neurology

Investigating macrophage-mediated inflammation in migraine using ultrasmall superparamagnetic iron oxide-enhanced 3T magnetic resonance imaging

Sabrina Khan et al.

CEPHALALGIA (2019)

Add to Collection

Article Clinical Neurology

Opening of ATP-sensitive potassium channels causes migraine attacks: a new target for the treatment of migraine

Mohammad Al-Mahdi Al-Karagholi et al.

BRAIN (2019)

Add to Collection

Article Clinical Neurology

Levcromakalim, an Adenosine Triphosphate-Sensitive Potassium Channel Opener, Dilates Extracerebral but not Cerebral Arteries

Mohammad Al-Mahdi Al-Karagholi et al.

HEADACHE (2019)

Add to Collection

Review Clinical Neurology

Migraine and the trigeminovascular system-40 years and counting

Messoud Ashina et al.

LANCET NEUROLOGY (2019)

Add to Collection

Article Clinical Neurology

Investigation of distinct molecular pathways in migraine induction using calcitonin gene-related peptide and sildenafil

Samaira Younis et al.

CEPHALALGIA (2019)

Add to Collection

Article Clinical Neurology

Meningeal contribution to migraine pain: a magnetic resonance angiography study

Sabrina Khan et al.

BRAIN (2019)

Add to Collection

Article Clinical Neurology

ARISE: A Phase 3 randomized trial of erenumab for episodic migraine

David W. Dodick et al.

CEPHALALGIA (2018)

Add to Collection

Article Clinical Neurology

Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition

Jes Olesen

CEPHALALGIA (2018)

Add to Collection

Article Pharmacology & Pharmacy

Sumatriptan inhibits the electrophysiological activity of ASICs in rat trigeminal ganglion neurons

Longhua Guo et al.

EUROPEAN JOURNAL OF PHARMACOLOGY (2018)

Add to Collection

Article Clinical Neurology

Migraine induction with calcitonin gene-related peptide in patients from erenumab trials

Casper Emil Christensen et al.

JOURNAL OF HEADACHE AND PAIN (2018)

Add to Collection

Article Clinical Neurology

Early onset of efficacy with erenumab in patients with episodic and chronic migraine

Todd Schwedt et al.

JOURNAL OF HEADACHE AND PAIN (2018)

Add to Collection

Article Clinical Neurology

Reproducibility of migraine-like attacks induced by phosphodiesterase-3-inhibitor cilostazol

Sabrina Khan et al.

CEPHALALGIA (2018)

Add to Collection

Article Clinical Neurology

Calcitonin gene-related peptide induced migraine attacks in patients with and without familial aggregation of migraine

Song Guo et al.

CEPHALALGIA (2017)

Add to Collection

Review Clinical Neurology

Human models of migraine - short-term pain for long-term gain

Messoud Ashina et al.

NATURE REVIEWS NEUROLOGY (2017)

Add to Collection

Article Medicine, General & Internal

A Controlled Trial of Erenumab for Episodic Migraine

Peter J. Goadsby et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Chemistry, Multidisciplinary

Pharmacokinetic-Pharmacodynamic Relationship of Erenumab (AMG 334) and Capsaicin-Induced Dermal Blood Flow in Healthy and Migraine Subjects

Thuy Vu et al.

PHARMACEUTICAL RESEARCH (2017)

Add to Collection

Article Pharmacology & Pharmacy

Pharmacologic Characterization of AMG 334, a Potent and Selective Human Monoclonal Antibody against the Calcitonin Gene-Related Peptide Receptor

Licheng Shi et al.

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2016)

Add to Collection

Article Clinical Neurology

A second trigeminal CGRP receptor: function and expression of the AMY1 receptor

Christopher S. Walker et al.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2015)

Add to Collection

Article Clinical Neurology

Phosphodiesterase 3 inhibitor cilostazol induces migraine-like attacks via cyclic AMP increase

Song Guo et al.

BRAIN (2014)

Add to Collection

Article Clinical Neurology

Phosphodiesterases 3 and 5 express activity in the trigeminal ganglion and co-localize with calcitonin gene-related peptide

Julie C. Nordgaard et al.

CEPHALALGIA (2014)

Add to Collection

Article Clinical Neurology

Pearls and pitfalls in human pharmacological models of migraine: 30 years' experience

Messoud Ashina et al.

CEPHALALGIA (2013)

Add to Collection

Article Neurosciences

Differences in phosphodiesterase 3A and 3B expression after ischemic insult

Yumiko Mitome-Mishima et al.

NEUROSCIENCE RESEARCH (2013)

Add to Collection

Article Neurosciences

Phosphodiesterase-3B is expressed in proopiomelanocortin and neuropeptide Y neurons in the mouse hypothalamus

Maitrayee Sahu et al.

NEUROSCIENCE LETTERS (2011)

Add to Collection

Article Clinical Neurology

Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura

Jakob Moller Hansen et al.

CEPHALALGIA (2010)

Add to Collection

Article Pharmacology & Pharmacy

Analysis of the effects of phosphodiesterase type 3 and 4 inhibitors in cerebral arteries

S Birk et al.

EUROPEAN JOURNAL OF PHARMACOLOGY (2004)

Add to Collection

Article Endocrinology & Metabolism

Cilostazol, an inhibitor of type 3 phosphodiesterase, stimulates large-conductance, calcium-activated potassium channels in pituitary GH3 cells and pheochromocytoma PC12 cells

SN Wu et al.

ENDOCRINOLOGY (2004)

Add to Collection

Article Endocrinology & Metabolism

The phosphodiesterase 3 inhibitor cilostazol dilates large cerebral arteries in humans without affecting regional cerebral blood flow

S Birk et al.

JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2004)

Add to Collection

© Peeref 2019-2024. All rights reserved.